Browse Studies — Arctuva

Phase 2

A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)

Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as a…

Macular DegenerationAge-Related Macular DegenerationChoroidal Neovascularization+1 more

Estimated

~$10 – $8,750

EyeBiotech Ltd.NCT07440225

Phase 2

A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)

Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as a…

Macular DegenerationAge-Related Macular DegenerationChoroidal Neovascularization+1 more

Estimated

~$10 – $8,750

EyeBiotech Ltd.NCT07496567

Phase 1

Phase I Clinical Study to Evaluate the Safety of CG-P5 Peptide Eye Drops (Self-administered and Topically Applied) in Patients Diagnosed With Age-related Wet Macular Degeneration

This will be a randomized, comparative, parallel, clinical study to assess initial safety and tolerability of CG-P5 peptide eye drops compared to placebo in pa…

Age-related Wet Macular Degeneration

Estimated

~$10 – $8,750

Caregen Co. Ltd.NCT06132035